Key result
Intravenous inotropes and/or vasopressors were associated with increased long-term all-cause mortality in acute heart failure (HR 1.434; 95% CI 1.128-1.823).
Why the study?
Do intravenous cardiovascular agents (vasodilators, inotropes, vasopressors) affect mortality in patients with acute heart failure?
Observational (n=6,926)
Yes
Do intravenous cardiovascular agents (vasodilators, inotropes, vasopressors) affect mortality in patients with acute heart failure?
Hazard Ratio: 1.434 (95% CI 1.128–1.823)
In acute heart failure, intravenous inotropes and vasopressors are associated with increased in-hospital and long-term mortality, whereas vasodilators are not associated with adverse long-term outcomes.
No takes yet. Share an insight, caveat, or question.
Supports cautious use of inotropes/vasopressors in acute HF; leaves open causality versus confounding by indication.
Mebazaa et al. (2017) conducted an observational in acute heart failure (n=6,926). intravenous inotropes and/or vasopressors vs. matched cohort without inotropes/vasopressors was evaluated on long-term all-cause mortality (HR 1.434, 95% CI 1.128-1.823). Intravenous inotropes and/or vasopressors were associated with increased long-term all-cause mortality in acute heart failure (HR 1.434; 95% CI 1.128-1.823).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: